SERUM PROTEIN PROFILES DIFFER WITH USTEKINUMAB AND ADALIMUMAB TREATMENT IN MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE

Swati Venkat  ¹     Martha Zeeman  ¹     Amy Hart  ¹     Sunita Bhagat  ¹     Dylan Richards  ¹     David A. Galbraith  ¹     Timothy Hoops  ²     Paul Ufberg  ²     James Izanec  ³     Thomas C. Freeman  ³     Bradford McRae  ³     Shinichiro Shinzaki  ⁴     Vipul Jairath  ⁵     Remo Panaccione  ⁶     Bruce E. Sands  ⁷     Patrick Branigan  ^7    
1 Janssen Research & Development, LLC, Spring House, United States
² Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, United States
³ Janssen Pharmaceuticals, LLC, Horsham, United States
⁴ Hyogo Medical University, Nishinomiya, Hyogo, Japan
⁵ University Hospital, London, Canada
⁶ University of Calgary, Calgary, Canada
⁷ Icahn School of Medicine at Mount Sinai, New York, United States

Topic
IBD

Session
PP 05 IBD (Posters)

Conference
UEG Week 2023

Citation
United European Gastroenterology Journal 2023; 11 (Supplement 8)